Eye Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Front Endocrinol (Lausanne). 2023 Apr 21;14:1183586. doi: 10.3389/fendo.2023.1183586. eCollection 2023.
Diabetic microangiopathy is a typical and severe problem in diabetics, including diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, and diabetic cardiomyopathy. Patients with type 2 diabetes and diabetic microvascular complications have significantly elevated levels of Asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase (NOS). ADMA facilitates the occurrence and progression of microvascular complications in type 2 diabetes through its effects on endothelial cell function, oxidative stress damage, inflammation, and fibrosis. This paper reviews the association between ADMA and microvascular complications of diabetes and elucidates the underlying mechanisms by which ADMA contributes to these complications. It provides a new idea and method for the prevention and treatment of microvascular complications in type 2 diabetes.
糖尿病性微血管病变是糖尿病患者的一种典型且严重的问题，包括糖尿病视网膜病变、糖尿病肾病、糖尿病神经病变和糖尿病心肌病。患有 2 型糖尿病和糖尿病微血管并发症的患者，其不对称二甲基精氨酸（ADMA）水平显著升高，ADMA 是一氧化氮合酶（NOS）的内源性抑制剂。ADMA 通过对内皮细胞功能、氧化应激损伤、炎症和纤维化的影响，促进 2 型糖尿病微血管并发症的发生和发展。本文综述了 ADMA 与糖尿病微血管并发症的关系，并阐明了 ADMA 导致这些并发症的潜在机制。为 2 型糖尿病微血管并发症的防治提供了新的思路和方法。
